Breaking News, Collaborations & Alliances

Charles River & Gates Institute Enter LVV CDMO Agreement

The Gates Institute will leverage Charles River’s cell and gene therapy CDMO expertise to develop lentiviral vectors for use in CAR T-cell therapies.

Author Image

By: Charlie Sternberg

Associate Editor

Charles River Laboratories International Inc. and the Gates Institute at the University of Colorado Anschutz Medical Campus have entered a lentiviral vector contract development and manufacturing organization (CDMO) agreement under which Gates Institute will leverage Charles River’s cell and gene therapy CDMO expertise to develop Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) for use in novel chimeric antigen receptor (CAR) T-cell therapies for hematological cancers.   “The ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters